With a quantity of roughly USD 33.0bn, the general financing for US biotech firms in 2021 but once more surpassed the entire funding of the earlier yr (USD 22.4bn). In comparison with 2020, the funding quantity elevated considerably by 47%.
With a complete of USD 9.2bn, the oncology sector acquired the best funding quantity, adopted by central nervous system (USD 6.0bn) and infectious illnesses (USD 2.2bn).
The most important deal of 2021 was the transaction of Treeline Biosciences (USD 735m), whereas probably the most lively investor was Alexandria Enterprise Investments with 51 investments in 2021.